{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:28:17Z","timestamp":1793028497552,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>This study aims to provide practical recommendations on prophylaxis for infection in pediatric patients with immune-mediated rheumatic diseases receiving\/scheduled to receive immunosuppressive therapy. A qualitative approach was applied. A narrative literature review was performed via Medline. Primary searches were conducted using MeSH terms and free text to identify articles that analyzed data on infections and vaccinations in pediatric patients with immune-mediated rheumatic diseases receiving immunosuppressive therapy. The results were presented and discussed in a nominal group meeting comprising a committee of 12 pediatric rheumatologists from the Prevention and Treatment of Infections Working Group of the Spanish Society of Pediatric Rheumatology. Several recommendations were generated. A consensus procedure was implemented via a Delphi process that was extended to members of the Spanish Society of Pediatric Rheumatology and the Vaccine Advisory Committee of the Spanish Association of Pediatrics. Participants produced a score ranging from 0 (completely disagree) to 10 (completely agree). Agreement was considered to have been reached if at least 70% of participants voted\u2009\u2265\u20097. The literature review included more than 400 articles. Overall, 63 recommendations were generated (23 on infection prophylaxis) and voted by 59 pediatric rheumatologists and other pediatric specialists, all of whom achieved the pre-established level of agreement. The recommendations on prophylaxis of infection cover vaccination and prophylaxis against varicella zoster virus, tuberculosis, <jats:italic>Pneumocystis jiroveccii<\/jats:italic>, and invasive fungal infections in pediatric patients with immune-mediated rheumatic diseases receiving\/scheduled to receive immunosuppressive therapy.<\/jats:p><jats:p>\u00a0 <jats:italic>Conclusion<\/jats:italic>: Based on current evidence and a Delphi process, we provided consensus and updated recommendations on prophylaxis and treatment of infections to guide those caring for pediatric rheumatology patients.\n<jats:table-wrap><jats:table><jats:tbody>\n                    <jats:tr>\n                      <jats:td align=\"left\"><jats:bold>What is Known:<\/jats:bold><\/jats:td>\n                    <\/jats:tr>\n                    <jats:tr>\n                      <jats:td align=\"left\">\u2022<jats:italic>Data largely derived from adults find that infectious diseases and related complications are a major cause of morbidity and mortality in patients with immune-mediated rheumatic diseases.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                    <jats:tr>\n                      <jats:td align=\"left\">\u2022<jats:italic>It is crucial to be aware of the preventive measures that should be implemented to prevent these infections in children, although most guidelines are often extrapolated from adult cases.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                    <jats:tr>\n                      <jats:td align=\"left\"><jats:bold>What is New:<\/jats:bold><\/jats:td>\n                    <\/jats:tr>\n                    <jats:tr>\n                      <jats:td align=\"left\">\u2022<jats:italic>In the absence of evidence, a literature review and a Delphi survey were conducted to establish a series of expert recommendations that could prove useful in clinical practice, providing a practical and simple day-to-day approach to be used by pediatric rheumatologists.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                    <jats:tr>\n                      <jats:td align=\"left\">\u2022<jats:italic>The recommendations focus on tuberculosis, herpes zoster virus, fungal infections, and Pneumocystis jirovecii.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>","DOI":"10.1007\/s00431-023-05080-3","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T06:03:39Z","timestamp":1689228219000},"page":"4271-4284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis"],"prefix":"10.1007","volume":"182","author":[{"given":"Daniel","family":"Clemente Garulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmeralda","family":"N\u00fa\u00f1ez-Cuadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Camacho Lovillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Calzada-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Guill\u00e9n Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fern\u00e1ndez Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Lirola Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Tagarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Mar\u00eda","family":"Alcobendas Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"L\u00f3pez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Satrustegi Aritziturri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"5080_CR1","doi-asserted-by":"crossref","unstructured":"Furer V, Rondaan C, Heijstek M, Van Assen S, Bijl M, Agmon-Levin N et al (2019) Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 5(2)","DOI":"10.1136\/rmdopen-2019-001041"},{"key":"5080_CR2","doi-asserted-by":"crossref","unstructured":"Heijstek MW, Ott De Bruin LM, Bijl M, Borrow R, Van Der Klis F, Kon\u00e9-Paut I et al (2011) EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 70(10):1704\u201312","DOI":"10.1136\/ard.2011.150193"},{"issue":"4","key":"5080_CR3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00296-020-04774-3","volume":"41","author":"F Thiele","year":"2021","unstructured":"Thiele F, Klein A, Windschall D, Hospach A, Foeldvari I, Minden K et al (2021) Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatol Int 41(4):751\u2013762","journal-title":"Rheumatol Int"},{"issue":"6","key":"5080_CR4","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s00431-022-04418-7","volume":"181","author":"E Cuadros","year":"2022","unstructured":"Cuadros E, Calzada-Hern\u00e1ndez J, Clemente D, Mart\u00edn S, Silveira L, Lirola-Cruz M et al (2022) Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening). Eur J Pediatr 181(6):2343\u20132354","journal-title":"Eur J Pediatr"},{"key":"5080_CR5","unstructured":"CEBM Medicine (2011) CfEB: CEBM levels of evidence 2011. http:\/\/www.cebm.net\/index.aspx?o=1025. Accessed 11 Apr 2013"},{"issue":"9","key":"5080_CR6","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/j.vaccine.2020.01.037","volume":"38","author":"Y Uziel","year":"2020","unstructured":"Uziel Y, Moshe V, Onozo B, Kulcs\u00e1r A, Tr\u00f3bert-Sipos D, Akikusa JD et al (2020) Live attenuated MMR\/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection. Vaccine 38(9):2198\u20132201","journal-title":"Vaccine"},{"key":"5080_CR7","doi-asserted-by":"crossref","unstructured":"Tse HN, Borrow R, Arkwright PD (2020) Immune response and safety of viral vaccines in children with autoimmune diseases on immune modulatory drug therapy. Expert Rev Vaccines 19:1115\u201327. Taylor and Francis Ltd","DOI":"10.1080\/14760584.2021.1875825"},{"key":"5080_CR8","doi-asserted-by":"crossref","unstructured":"Blanchard-Rohner G (2021) Vaccination in children with autoimmune disorders and treated with various immunosuppressive regimens: a comprehensive review and practical guide. Front Immunol 12(711637)","DOI":"10.3389\/fimmu.2021.711637"},{"issue":"7","key":"5080_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/acr.20183","volume":"62","author":"GS Pileggi","year":"2010","unstructured":"Pileggi GS, De Souza CBS, Ferriani VPL (2010) Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res (Hoboken) 62(7):1034\u20131039","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"21","key":"5080_CR10","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1016\/j.vaccine.2017.04.015","volume":"35","author":"N Groot","year":"2017","unstructured":"Groot N, Pileggi G, Sandoval CB, Grein I, Berbers G, Ferriani VPL et al (2017) Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment. Vaccine 35(21):2818\u20132822","journal-title":"Vaccine"},{"key":"5080_CR11","doi-asserted-by":"crossref","unstructured":"Jos\u00e9 \u00c1lvarez Garc\u00eda F, Jos\u00e9 M, Ortega C, Alde\u00e1n J\u00c1, Garc\u00e9s-S\u00e1nchez M, Llanos EG et al (2022) Immunization schedule of the Pediatric Spanish Association: 2022 recommendations. An Pediatr (Engl Ed) 96:1\u201359","DOI":"10.1016\/j.anpede.2021.11.002"},{"issue":"11","key":"5080_CR12","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1093\/rheumatology\/kes202","volume":"51","author":"ILA Fran\u00e7a","year":"2012","unstructured":"Fran\u00e7a ILA, Ribeiro ACM, Aikawa NE, Saad CGS, Moraes JCB, Goldstein-schainberg C et al (2012) TNF blockers show distinct patterns of immune response to the pandemic influenza a H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford) 51(11):2091\u20132098","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"5080_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/ard.2007.077552","volume":"67","author":"LBS Gelinck","year":"2008","unstructured":"Gelinck LBS, Van Der Bijl AE, Beyer WEP, Visser LG, Huizinga TWJ, Van Hogezand RA et al (2008) The effect of anti-tumour necrosis factor \u03b1 treatment on the antibody response to influenza vaccination. Ann Rheum Dis 67(5):713\u2013716","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5080_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s10875-012-9813-x","volume":"33","author":"RA Eisenberg","year":"2013","unstructured":"Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ETL et al (2013) Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 33(2):388\u2013396","journal-title":"J Clin Immunol"},{"issue":"3","key":"5080_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3109\/14397595.2013.843743","volume":"24","author":"T Tsuru","year":"2014","unstructured":"Tsuru T, Terao K, Murakami M, Matsutani T, Suzaki M, Amamoto T et al (2014) Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol 24(3):511\u2013516","journal-title":"Mod Rheumatol"},{"issue":"5","key":"5080_CR16","doi-asserted-by":"publisher","first-page":"317.e1","DOI":"10.1016\/j.anpedi.2019.01.009","volume":"90","author":"A Tagarro","year":"2019","unstructured":"Tagarro A, Cruz-Ca\u00f1ete M, Otheo E, Launes C, Couceiro JA, P\u00e9rez C et al (2019) Oseltamivir for the treatment of influenza in children and adolescents. An Pediatr (Engl Ed) 90(5):317.e1-317.e8","journal-title":"An Pediatr (Engl Ed)"},{"key":"5080_CR17","unstructured":"Public Health England. Guidance for issuing varicella-zoster immunoglobulin (VZIG).https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/811544\/VZIG_issuing_guidance.pdf."},{"issue":"4","key":"5080_CR18","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/rheumatology\/kex519","volume":"57","author":"M Cates","year":"2018","unstructured":"Cates M, Donati M, Gillet S, Ustianowski A, Galloway J (2018) Comment on: managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy. Rheumatology (Oxford) 57(4):768","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"5080_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/rheumatology\/kex189","volume":"57","author":"M Cates","year":"2018","unstructured":"Cates M, Donati M, Gillet S, Ustianowski A, Galloway J (2018) Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy. Rheumatology (Oxford) 57(4):596\u2013605","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"5080_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2165\/00003088-200443100-00004","volume":"43","author":"F Gimenez","year":"2004","unstructured":"Gimenez F, Foeillet E, Bourdon O, Weller S, Garret C, Bidault R et al (2004) Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharmacokinet 43(10):685\u2013692","journal-title":"Clin Pharmacokinet"},{"key":"5080_CR21","doi-asserted-by":"crossref","unstructured":"Baquero-Artigao F, del Rosal T, Falc\u00f3n-Neyra L, Ferreras-Antol\u00edn L, G\u00f3mez-Pastrana D, Hernanz-Lobo A et al (2023) Update on the diagnosis and treatment of tuberculosis. Anales de Pediatr\u00eda (English Edition) 98(6):460\u20139. Available from\u00a0https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2341287923001084","DOI":"10.1016\/j.anpede.2023.03.009"},{"key":"5080_CR22","doi-asserted-by":"crossref","unstructured":"Nolt D, Starke JR (2021) Tuberculosis infection in children and adolescents: testing and treatment. Pediatrics 148(6)","DOI":"10.1542\/peds.2021-054663"},{"key":"5080_CR23","doi-asserted-by":"crossref","unstructured":"Yang Y, Wang HJ, Hu WL, Bai GN, Hua CZ (2022) Diagnostic value of interferon-gamma release assays for tuberculosis in the immunocompromised population. Diagnostics (Basel) 12(2)","DOI":"10.3390\/diagnostics12020453"},{"issue":"2","key":"5080_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cid\/ciw778","volume":"64","author":"DM Lewinsohn","year":"2017","unstructured":"Lewinsohn DM, Leonard MK, Lobue PA, Cohn DL, Daley CL, Desmond E et al (2017) Official American thoracic society\/Infectious diseases society of America\/Centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis 64(2):111\u2013115","journal-title":"Clin Infect Dis"},{"key":"5080_CR25","doi-asserted-by":"crossref","unstructured":"Moreno-P\u00e9rez D, Andr\u00e9s Mart\u00edn A, Altet G\u00f3mez N, Baquero-Artigao F, Escribano Montaner A, G\u00f3mez-Pa\u00edstrana Dur\u00e1n D et al (2010) Diagnosis of tuberculosis in paediatrics. An Pediatr (Engl Ed) 72:283.e1\u2013283.e14","DOI":"10.1016\/j.anpedi.2010.01.002"},{"issue":"3","key":"5080_CR26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.rbr.2016.11.005","volume":"57","author":"JCL J\u00fanior","year":"2017","unstructured":"J\u00fanior JCL, Ramos RTT, Robazzi TCMV (2017) Treatment of latent tuberculosis in patients with juvenile rheumatic diseases: a systematic review. Rev Bras Reumatol Engl Ed 57(3):245\u2013253","journal-title":"Rev Bras Reumatol Engl Ed"},{"issue":"10","key":"5080_CR27","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1164\/rccm.201909-1874ST","volume":"200","author":"P Nahid","year":"2019","unstructured":"Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL et al (2019) Treatment of drug-resistant tuberculosis an official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med 200(10):E93-142","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"5080_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/myc.12576","volume":"60","author":"A Tragiannidis","year":"2017","unstructured":"Tragiannidis A, Kyriakidis I, Z\u00fcndorf I, Groll AH (2017) Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-\u03b1) inhibitors. Mycoses 60(4):222\u2013229","journal-title":"Mycoses"},{"issue":"8","key":"5080_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/myc.12621","volume":"60","author":"I Kyriakidis","year":"2017","unstructured":"Kyriakidis I, Tragiannidis A, Z\u00fcndorf I, Groll AH (2017) Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors. Mycoses 60(8):493\u2013507","journal-title":"Mycoses"},{"issue":"2","key":"5080_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","volume":"97","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M et al (2018) Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol 97(2):197\u2013207","journal-title":"Ann Hematol"},{"issue":"6","key":"5080_CR31","first-page":"1018","volume":"35","author":"M Galli","year":"2017","unstructured":"Galli M, Antinori S, Atzeni F, Meroni L, Riva A, Scir\u00e8 C et al (2017) Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clin Exp Rhumatol 35(6):1018\u20131028","journal-title":"Clin Exp Rhumatol"},{"issue":"9","key":"5080_CR32","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0961203313496342","volume":"22","author":"JP Vinicki","year":"2013","unstructured":"Vinicki JP, Pellet SC, Pappalardo C, Cruzat VC, Spinetto MA, Dubinsky D et al (2013) Invasive fungal infections in Argentine patients with systemic lupus erythematosus. Lupus 22(9):892\u2013898","journal-title":"Lupus"},{"issue":"7","key":"5080_CR33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/0961203309103081","volume":"18","author":"HJ Kim","year":"2009","unstructured":"Kim HJ, Park YJ, Kim WU, Park SH, Cho CS (2009) Invasive fungal infections in patients with systemic lupus erythematosus: experience from affiliated hospitals of Catholic University of Korea. Lupus 18(7):661\u2013666","journal-title":"Lupus"},{"issue":"9","key":"5080_CR34","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3899\/jrheum.180795","volume":"46","author":"M Pardeo","year":"2019","unstructured":"Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R et al (2019) Neutropenia during tocilizumab treatment is not associated with infection risk in systemic or polyarticular-course juvenile idiopathic arthritis. J Rheumatol 46(9):1117\u20131126","journal-title":"J Rheumatol"},{"issue":"4","key":"5080_CR35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.prrv.2009.06.010","volume":"10","author":"V Pyrgos","year":"2009","unstructured":"Pyrgos V, Shoham S, Roilides E, Walsh TJ (2009) Pneumocystis pneumonia in children. Paediatr Respir Rev 10(4):192\u2013198","journal-title":"Paediatr Respir Rev"},{"issue":"4","key":"5080_CR36","first-page":"283","volume":"7","author":"ML Basiaga","year":"2018","unstructured":"Basiaga ML, Ross ME, Gerber JS, Ogdie A (2018) Incidence of Pneumocystis jirovecii and adverse events associated with pneumocystis prophylaxis in children receiving glucocorticoids. J Pediatric Infect Dis Soc 7(4):283\u2013289","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"5","key":"5080_CR37","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77(5):644\u2013649","journal-title":"Ann Rheum Dis"},{"key":"5080_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.anpedi.2020.04.031","volume":"95","author":"L Mart\u00edn Pedraz","year":"2021","unstructured":"Mart\u00edn Pedraz L, Carazo Gallego B, Moreno PD (2021) Clinical-epidemiological characteristics of Pneumocystis jirovecii pneumonia in a tertiary hospital in Spain. An Pediatr (Engl Ed) 95:4\u201310","journal-title":"An Pediatr (Engl Ed)"},{"issue":"12","key":"5080_CR39","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.medcli.2019.01.010","volume":"152","author":"BP Braga","year":"2019","unstructured":"Braga BP, Prieto-Gonz\u00e1lez S, Hern\u00e1ndez-Rodr\u00edguez J (2019) Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases. Med Clin (Barc) 152(12):502\u2013507","journal-title":"Med Clin (Barc)"},{"key":"5080_CR40","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1007\/s10067-021-05660-4","volume":"40","author":"HC Hsu","year":"2021","unstructured":"Hsu HC, Chang YS, Hou TY, Chen LF, Hu LF, Lin TM et al (2021) Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study. Clin Rheumatol 40:3755\u20133763","journal-title":"Clin Rheumatol"},{"key":"5080_CR41","first-page":"10","volume":"15","author":"A Dunbar","year":"2020","unstructured":"Dunbar A, Schauwvlieghe A, Algoe S, van Hellemond JJ, Reynders M, Vandecasteele S et al (2020) Epidemiology of Pneumocystis jirovecii pneumonia and (non-)use of prophylaxis. Front Cell Infect Microbiol 15:10","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"5080_CR42","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.semarthrit.2018.10.018","volume":"48","author":"G Schmajuk","year":"2019","unstructured":"Schmajuk G, Jafri K, Evans M, Shiboski S, Gianfrancesco M, Izadi Z et al (2019) Pneumocystis jirovecii pneumonia (PJP)prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Semin Arthritis Rheum 48(6):1087\u20131092","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"5080_CR43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/annrheumdis-2017-212588","volume":"77","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Baddley JW (2018) Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); That is the question. Ann Rheum Dis 77(5):631\u2013633","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5080_CR44","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/mus.27481","volume":"65","author":"B Claytor","year":"2022","unstructured":"Claytor B, Li Y (2022) Opinions on Pneumocystis jirovecii prophylaxis in autoimmune neuromuscular disorders. Muscle Nerve 65(3):278\u2013283","journal-title":"Muscle Nerve"},{"issue":"3","key":"5080_CR45","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, De Groot K, Gross W et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310\u2013317","journal-title":"Ann Rheum Dis"},{"key":"5080_CR46","doi-asserted-by":"crossref","unstructured":"Moosig F, Holle JU, Gross WL (2009) Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis ResTher 11(5)","DOI":"10.1186\/ar2826"},{"issue":"3","key":"5080_CR47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/eci.12410","volume":"45","author":"A Kronbichler","year":"2015","unstructured":"Kronbichler A, Jayne DRW, Mayer G (2015) Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 45(3):346\u2013368","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"5080_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.berh.2013.01.004","volume":"27","author":"L Guillevin","year":"2013","unstructured":"Guillevin L (2013) Infections in vasculitis. Best Pract Res Clin Rheumatol 27(1):19\u201331","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"5080_CR49","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T et al (2016) EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75(9):1583\u20131594","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"5080_CR50","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/rheumatology\/ken234","volume":"47","author":"LL Teichmann","year":"2008","unstructured":"Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Sch\u00f6lmerich J, Fleck M (2008) Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 47(8):1256\u20131257","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"5080_CR51","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s10067-013-2293-4","volume":"32","author":"E Besada","year":"2013","unstructured":"Besada E, Nossent JC (2013) Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis? Clin Rheumatol 32(11):1677\u20131681","journal-title":"Clin Rheumatol"},{"issue":"3","key":"5080_CR52","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10067-013-2475-0","volume":"33","author":"F Bonilla-Abad\u00eda","year":"2014","unstructured":"Bonilla-Abad\u00eda F, Betancurt JF, Pineda JC, V\u00e9lez JD, Tob\u00f3n GJ, Ca\u00f1as CA (2014) Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy. Clin Rheumatol 33(3):415\u2013418","journal-title":"Clin Rheumatol"},{"key":"5080_CR53","doi-asserted-by":"crossref","unstructured":"Zalmanovich A, Ben-Ami R, Rahav G, Alon D, Moses A, Olshtain-Pops K et al (2020) Rituximab identified as an independent risk factor for severe PJP: a case-control study. PLoS One 15(9 September)","DOI":"10.1371\/journal.pone.0239042"},{"issue":"50","key":"5080_CR54","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.ejim.2017.11.014","volume":"1","author":"K Alexandre","year":"2018","unstructured":"Alexandre K, Ingen-Housz-Oro S, Versini M, Sailler L, Benhamou Y (2018) Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: report of 11 cases and review of the literature. Eur J Int Med 1(50):e23\u2013e24","journal-title":"Eur J Int Med"},{"issue":"10","key":"5080_CR55","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11926-014-0445-4","volume":"16","author":"JA Grubbs","year":"2014","unstructured":"Grubbs JA, Baddley JW (2014) Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis. Curr Rheumatol Rep 16(10):445\u2013454","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"5080_CR56","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/art.24283","volume":"61","author":"Y Komano","year":"2009","unstructured":"Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa JUN, Saito K et al (2009) Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Care Res 61(3):305\u2013312","journal-title":"Arthritis Care Res"},{"issue":"6","key":"5080_CR57","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3109\/s10165-012-0615-z","volume":"22","author":"M Tanaka","year":"2012","unstructured":"Tanaka M, Sakai R, Koike R, Komano Y, Nanki T, Sakai F et al (2012) Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol 22(6):849\u2013858","journal-title":"Mod Rheumatol"},{"issue":"6","key":"5080_CR58","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3109\/s10165-012-0796-5","volume":"23","author":"K Watanabe","year":"2013","unstructured":"Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M et al (2013) Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. Mod Rheumatol 23(6):1085\u20131093","journal-title":"Mod Rheumatol"},{"issue":"12","key":"5080_CR59","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00296-014-3073-4","volume":"34","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Zheng Y (2014) Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int 34(12):1765\u20131771","journal-title":"Rheumatol Int"},{"key":"5080_CR60","doi-asserted-by":"crossref","unstructured":"Messiaen PE, Cuyx S, Dejagere T, van der Hilst JC (2017) The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: a systematic review. Transpl Infect Dis 19(2)","DOI":"10.1111\/tid.12651"},{"issue":"3","key":"5080_CR61","first-page":"490","volume":"36","author":"G Baulier","year":"2018","unstructured":"Baulier G, Issa N, Gabriel F, Accoceberry I, Camou F, Duffau P (2018) Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases. Clin Exp Rheumatol 36(3):490\u2013493","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"5080_CR62","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3899\/jrheum.090843","volume":"37","author":"D Cettomai","year":"2010","unstructured":"Cettomai D, Gelber AC, Christopher-Stine L (2010) A survey of rheumatologists\u2019 practice for prescribing pneumocystis prophylaxis. J Rheumatol 37(4):792\u2013799","journal-title":"J Rheumatol"},{"key":"5080_CR63","doi-asserted-by":"crossref","unstructured":"Pereda CA, Nishishinya-Aquino MB, Brito-Garc\u00eda N, D\u00edaz del Campo Fontecha P, Rua-Figueroa I (2021) Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies? Rheumatol Int 41(8):1419\u201327","DOI":"10.1007\/s00296-021-04808-4"},{"issue":"11","key":"5080_CR64","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1136\/archdischild-2015-309100","volume":"100","author":"A Boast","year":"2015","unstructured":"Boast A, Osowicki J, Cole T, Curtis N, Gwee A (2015) Question 1: Co-trimoxazole dosing dilemma: what is the right dose? Arch Dis Child 100(11):1089\u20131093","journal-title":"Arch Dis Child"},{"key":"5080_CR65","doi-asserted-by":"crossref","unstructured":"Ishikawa Y, Nakano K, Tokutsu K, Miyata H, Fujino Y, Matsuda S et al (2021) Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases. RMD Open 7(1)","DOI":"10.1136\/rmdopen-2020-001508"},{"issue":"1","key":"5080_CR66","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/annrheumdis-2022-222574","volume":"82","author":"MHA Jansen","year":"2023","unstructured":"Jansen MHA, Rondaan C, Legger GE, Minden K, Uziel Y, Toplak N et al (2023) EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis 82(1):35\u201347","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"5080_CR67","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1016\/j.vaccine.2023.04.056","volume":"41","author":"M Ohm","year":"2023","unstructured":"Ohm M, van Straalen JW, Zijlstra M, de Joode-Smink G, Jasmijn Sellies A, Swart JF et al (2023) Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: a prospective observational cohort study. Vaccine 41(25):3782\u20133789","journal-title":"Vaccine"},{"issue":"11","key":"5080_CR68","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/rheumatology\/keac431","volume":"61","author":"ES Sen","year":"2022","unstructured":"Sen ES, Julandani D, Ramanan AV (2022) SARS-CoV-2 vaccinations in children and adolescents with rheumatic diseases. Rheumatology (Oxford) 61(11):4229\u20134231","journal-title":"Rheumatology (Oxford)"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-023-05080-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T04:03:52Z","timestamp":1697169832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-023-05080-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":68,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["5080"],"URL":"https:\/\/doi.org\/10.1007\/s00431-023-05080-3","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"assertion":[{"value":"16 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}